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a  b  s  t r  a  c  t
Human  glutathione  transferase  T2-2  (GSTT2-2)  is  one  of  the  enzymes  considered  to  play  a role  in inac-
tivation  of  toxicants  and  carcinogens.  The  expression  level  of  this  enzyme  is determined  by  genetic  and
environmental  factors,  which  may  lead to  differences  in susceptibility.  As  a specific  assay  for GSTT2-2
so  far a spectroscopical  assay  based  on  GSH-conjugation  of  menaphthyl  sulfate  (MSu)  was  used.  This
spectrophotometric  assay,  however,  appeared  too  insensitive  to accurately  quantify  the  GSTT2-2  activ-
ities  in  a  panel  of  20  human  liver  samples.  More  recently,  expression  levels  of  GSTT2-2  in biological
samples  are  quantified  by measuring  mRNA  levels.  Since  mRNA-levels  do  not  always  correlate  well
with  enzyme  activity,  a specific  and  sensitive  assay  is  required.  In the  present  study  a highly  sensi-
tive  high-performance  liquid  chromatography  (HPLC)-based  method  was  developed.  By applying  the
new method,  firstly,  the  specificity  of  GSTT2-2  among  15 recombinant  human  GST  isoforms  in catalyz-
ing  GSH-conjugation  of  MSu  was  confirmed.  In addition,  a 65-fold  inter-individual  variation  of  GSTT2-2
activity  was  found  from  the  individual  liver  fractions.  By  applying  the  method  to individual  liver  frac-
tions,  a  65-fold  inter-individual  variation  of  GSTT2-2  activity  was  found.  As  a second  application,  the
role  of GSTT2-2  in  GSH-conjugation  of  the  environmental  carcinogen  1-methylpyrene  sulfate  (MPS)  was
studied  by  correlation  analysis  with  GSTT2-2-catalyzed  MSu  conjugation.  The  relatively  poor  correla-
tion  suggested  that  other  GSTs  also contribute  to MPS-conjugation,  as  confirmed  by  incubations  with
recombinant  GSTs.
. IntroductionHuman glutathione transferases (GSTs) are important phase II
nzymes ubiquitously expressed in different tissues. Because they
atalyze the inactivation of electrophiles and hydroperoxides using
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the cofactor glutathione (GSH), they play an important protective
role in the elimination of potentially toxic and carcinogenic chem-
icals, including drugs, pesticides, and environmental pollutants.
Based on their subcellular localizations, human GSTs can be divided
into three subclasses namely cytosolic GSTs, microsomal GSTs and
mitochondrial GSTs [1]. The cytosolic human GSTs are dimeric pro-
teins and are the most extensively-studied subclass regarding their
contributions as a protective enzyme system. The human cytosolic
GSTs are further divided in seven distinct classes: Alpha (A), Mu  (M),
Pi (P), Theta (T), Omega (O), Sigma (S), and Zeta (Z). Amongst them,
the GST theta class enzymes are relatively less studied compared
to the major cytosolic GSTs. However, the genetic polymorphisms
of Theta class GSTs have been associated with increased risk for
chemical-induced DNA-damage which my lead to increased risk of
cancers [2].The human Theta class GST is composed of two  isoforms,
GSTTT1-1 and GSTT2-2. These GSTs differ from the other cytosolic
enzymes by having a relatively low affinity to GSH, which explains
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hat they cannot be isolated from tissue extracts by GSH affinity
hromatography [3]. Furthermore, GSTT1-1 and GSTT2-2 do not
onjugate 1-chloro-2,4-dinitrobenzene (CDNB), which is a general
ubstrate for all other GSTs [4]. Substrates for the theta class GSTs
re 1,2-epoxy-3-(p-nitrophenoxy)propane (EPNP) which is selec-
ive for GSTT1-1 and 1-menaphthyl sulfate (MSu) which appeared
o be a substrate for GSTT2-2 [4,5]. However, the selectivity of
SH-conjugation of MSu  for GSTT2-2 has not been studied with
he full spectrum of human GSTs yet. So far, the GSH-conjugation
f MSu  has been performed by a spectrophotometric method [6].
lthough this method has advantages of low-cost lab facilities and
uick assay duration, disadvantages are the lacking of sensitiv-
ty and accuracy with complicated matrices. These disadvantages
imit its application to samples with low GSTT2-2 expression lev-
ls, such as cell lines. As alternative methods to determine GSTT2-2
xpression levels, mRNA levels and western blot assays are used
7,8]. However, it has been demonstrated that mRNA-levels of drug
etabolizing enzymes sometimes poorly correlate with protein
evels and enzyme activity [9,10]. Furthermore, western blot anal-
sis is not able to distinguish between active and inactive enzymes.
herefore, a more sensitive method for measuring of GSTT2-2-
atalyzed GSH-conjugation of MSu  is required.
Although it has been demonstrated by immunochemical meth-
ds that human GSTT2-2 is expressed in multiple organs, the
xpression level and variability of GSTT2-2 activity in human tis-
ues is still poorly studied. Inter-individual variability of GSTs
s generally considered to have a significant impact on internal
xposure to reactive drug metabolites, which may  thereby affect
usceptibility to toxicity and carcinogenicity [1]. Although in con-
rast to GSTT1-1, no null genotype has been identified for GSTT2,
 deletion of the neighboring GSTT2b pseudogene was  shown to
esult in a very strong decrease in the enzyme expression level
11]. This deletion has been associated with an increased risk of
sophageal squamous cell carcinoma [12]. Furthermore, a G537A
utation in the promotor area of GSTT2,  which leads to lower tran-
cription of GSTT2,  has been associated with an increased risk for
olorectal cancer [13].
Mutagens that have been identified as substrates for GSTT2-
 include N-acetoxy-PhIP, secondary lipid peroxidation products,
rganic hydroperoxides, and sulfate esters of methylated poly-
yclic aromatic hydrocarbons (PAHs) [14]. The selectivity towards
ulfate esters can be rationalized by the presence of a sulfate bind-
ng pocket which was found in the crystal structure of GSTT2-2
15]. 1-Methylpyrene (MP) is one of the methylated polycyclic
romatic hydrocarbons and has been detected in cigarette smoke
t levels exceeding that of benzo[]pyrene [16,17]. As the ulti-
ate carcinogen of MP,  1-methylpyrene sulfate (MPS) is formed
y sequential benzylic hydroxylation and sulfation by catalysis
f sulfotransferases. MPS  has been shown to bind covalently to
NA forming N2-(1-methylpyrenyl)-2′-deoxyguanosine (MPdG)
nd N6-(1-methylpyrenyl)-2′-deoxyadenosine (MPdA) in in vitro
nd in vivo experiments [18]. The excretion of S-((pyrene-1-yl)
ethyl) N-acetylcysteine (MPMA) in rat urine [19] indicated an
nvolvement of GSH-conjugation pathway in vivo. Although several
on-reactive sulfate esters of methylated PAHs have been tested
ith GSTT2-2, the role of human GSTs in detoxifying MPS has not
een characterized yet.
The major aims of the present study were, i) to establish a
ensitive HPLC-UV-based method to enable accurate quantifica-
ion of human GST T2-2 activity using MSu  as a substrate; ii) to
pply this method for the characterization of the specificity in
atalyzing MSu  GSH-conjugation by comparing 15 recombinant
uman GSTs; iii) to determine the inter-individual variation of
nzyme activity and to estimate the expression level of GSTT2-2
n a panel of human liver cytosol (HLC) from 20 different donors;
v) to characterize the role of GSTT2-2 in the detoxification ofiomedical Analysis 156 (2018) 181–188
MPS  by applying correlation analysis and recombinant human
GSTs.
2. Materials and methods
2.1. Materials
Recombinant human GST isoforms A1-1, A2-2, A3-3, A4-4, M1-
1, M2-2, M3-3, M4-4, P1-1*A, P1-1*B, P1-1*C, P1-1*D, K1-1, T1-1,
and T2-2 were expressed and purified according to the proto-
cols published previously [20]. Pooled HLC was purchased from
BD Biosciences (Breda, The Netherlands). Individual HLC was pre-
pared from liver fractions from 20 donors kindly provided by
Kaly-Cell (Strassbourg, France). MSu  and S-(1-menaphthyl) glu-
tathione (MSG) were synthesized according to previously described
methods [21,22]. MPS  was kindly provided by Prof. Hansruedi
Glatt (German Institute of Human Nutrition, Berlin, Germany). GSH,
ammonium acetate, formic acid and ammonium hydroxide were
obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands). All
other chemicals and reagents were of analytical grade and obtained
from standard suppliers.
2.2. Analysis of GSH-conjugation of MSu  by spectrophotometry
and by HPLC-UV
The GSH-conjugation of MSu  was  determined by the spec-
trophotometric method as described by [8]. Incubations were
performed in a final volume of 1 mL  100 mM Kpi buffer pH 7.4 (pre-
pared by mixing 100 mM  KH2PO4 and 100 mM KH2PO4 at ratio of
1.98:8.02) containing recombinant human GSTs or HLC (pooled and
individual), 5 mM GSH and 100 M Msu  and at an incubation tem-
perature of 37 ◦C. After starting the reaction by addition of GSH, the
increase in absorbance at 298 nm was recorded for 10 min using an
Ultrospec 2000 UV/visible spectrophotometer (Pharmacia Biotech,
Cambridge, England).
The purposed HPLC-UV method, more accurate and sensitive
than the spectrophotometric one, was developed to quantify the
enzyme activity in incubations with HLC. To this end, incubations
as described above were terminated by the addition of 1% perchlo-
ric acid (HClO4) (final concentration) and centrifuged at 14,000 rpm
to precipitate the proteins. The supernatants were analyzed on a
Shimadzu HPLC system consisting of two  LC-20AD binary pumps,
a SIL-20AC auto-sampler (cooled at 4 ◦C), and a SPD-20A UV/VIS
detector set at 298 nm. Chromatographic separation of analytes
was performed with a Luna 5 m C8 column (50 mm × 3 mm)  and a
gradient composed of solvent A (10 mM ammonium acetate, pH 8.0
adjusted with ammonium hydroxide) and solvent B (100% acetron-
itrile). The flow rate was set at 0.5 mL/min and the gradient was
programmed as follows: 0–2 min, isocratic 10% B; 2–12.5 min, lin-
ear increase from 10% B to 35%B, 12.5–13 min, linear increase from
35% B to 99% B; 13–13.5 min, linear decrease from 99% B to 10% B;
13.5–20 min  isocratic at 10% B.
2.3. Isoenzyme selectivity of GST-catalyzed GSH conjugation of
MSu
Previous studies on the specificity of GSH-conjugation by
GSTT2-2 were performed with an incomplete set of human GSTs.
Therefore, in the present study 15 recombinant human GSTs were
incubated at a GST concentration of 50 nM with 100 M MSu  at
37 ◦C for 10 min. The major hepatic GST isoforms, GSTA1-1, A2-
2, and M1-1 were also incubated at an enzyme concentration of
100 M,  which is the highest concentration found in HLC [23,24].
All incubations were performed in 100 mM potassium phosphate
(KPi) buffer, pH 7.4, in the presence of 5 mM GSH at a final volume
of 200 L in duplicate. Incubations were initiated by the addition
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Fig. 1. Representative chromatograms of MSG  and MSu  from standard and incuba-
tion samples, analyzed by HPLC-UV-based assay established in the current study.












rence sample at 6.5 M;  (C) incubation sample containing only 100 M MSu  and
 mM GSH; (D) incubation sample of 100 M MSu  with 0.2 M recombinant human
STT2-2 in the presence of 5 mM GSH; (E) incubation sample of 100 M MSu  with
% of human liver cytosol from donor S1399T in the presence of 5 mM GSH.
f MSu  and terminated with ice-cold HClO4 at a final concentration
f 1% (v/v) and cooled on ice for 10 min. Precipitates were removed
y centrifugation for 15 min  at 14,000 rpm. The supernatants were
nalyzed by HPLC-UV as described in Section 2.2.
.4. Enzyme kinetics of GSH conjugation of MSu  catalyzed by
ecombinant human GSTT2-2 and pooled HLC
The enzyme kinetical parameters of GSH conjugation of MSu
y recombinant hGSTT2-2 were determined by varying the MSu-Fig. 2. Calibration curve of MSG  ranging from 0.13 to 32.5 M.
concentration from 0.5 to 50 M.  Incubations were performed
at 37 ◦C in 100 mM KPi buffer, pH 7.4, in the presence of 5 mM
GSH and 50 nM recombinant human GSTT2-2. This concentration
of GSTT2-2 was selected based on the linear range of enzyme
concentration-dependency of MSG  formation (Supplemental Fig.
S1). All incubations were performed in a total volume of 200 L and
were pre-incubated at 37 ◦C for 5 min. Reactions were started by the
addition of GSH. After 2 min, the incubations were terminated by
addition of HClO4 (1% final concentration, v/v). The analysis of sam-
ples was  conducted by the HPLC-UV method as described in Section
2.2. Enzyme kinetics of GSH conjugation of MSu  with pooled HLC
were performed using 0.72 mg/mL  HLC. MSu  concentrations rang-
ing from 0.1 to 50 M were used to study the enzyme kinetics.
Incubations were performed at 37 ◦C for 10 min based on linearity
of reaction (Supplemental Fig. S2). All other conditions were the
same as described for recombinant human GSTT2-2.
Enzyme kinetical parameters were calculated by nonlinear
regression using the Michaelis–Menten equation or the substrate
inhibition equation with GraphPad Prism 5 software (San Diego,
CA, USA).
2.5. Characterization of GSTs involved in the GSH-conjugation of
MPS
To investigate which GSTs are able to catalyze GSH-conjugation
of MPS, MPS  was incubated at a concentration of 100 M with
the 15 available recombinant human GST isoforms at an enzyme
concentration of 8 M.  Incubations were performed in 100 mM
KPi buffer, pH 7.4, in the presence of 5 mM GSH for 1 h at 37 ◦C.
Reactions were started by adding MPS  and terminated by adding
an equal volume of ice-cold acetonitrile. Samples were cooled on
ice for 10 min  and centrifuged for 15 min  at 14000 rpm. The GSH-
conjugate formed, MP-SG, was  quantified using the HPLC method
of Reinen et al. [25], with minor modifications. Samples at 50 L
of supernatant were analyzed using a Shimadzu HPLC system con-
sisting of two  LC-20AD binary pumps, a SIL-20AC auto-sampler,
and a SPD-20A UV/VIS detector coupled with a reversed-phase C18
column (ChromSpher, 5 m,  100 × 3 mm,  Chrompack, Middelburg,
The Netherlands). A gradient composed of solvent A (5% of acetoni-
trile and 95% of 10 mM ammonium acetate, pH adjusted to 5 with
formic acid) and solvent B (95% of acetonitrile and 5% of 10 mM
ammonium acetate) was used. The gradient was programmed as
follows: gradient elution from 5% B to 90% B for 4.5 min, isocratic
elution at 90% B for 4 min, gradient elution back to 5% B from 8.5
to 9 min, and isocratic elution at 5% B from 9 to 15 min. The flow
rate was  0.5 mL/min and UV detection was set at a wavelength of
346 nm.  MP-SG reference was  obtained by quantitative conversion
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Fig. 3. Comparison of HPLC–based and spectrophotometric assays for GSTT2-2 activity measurement in pooled human liver cytosol (HLC) using MSu as a substrate. (A) UV
spectra  of absorbance at 298 nm of incubations containing 0.144 (black), 0.288 (blue), and 0.72 (red) mg/mL  pooled HLC; (B) HPLC chromatograms of MSG formation from















For  interpretation of the references to colour in this figure legend, the reader is ref
f samples with varying concentrations of MPS, since MP-SG is the
nly metabolite in this biotransformation reaction. The standard
urve of MP-SG appeared linear within the range of 0.26–52.63 M.
The correlation between GST-conjugation of MPS  and MSu  was
tudied by using a panel of HLC from 20 donors. Each individ-
al HLC fraction was incubated for 30 min  at 37 ◦C with 100 M
Su  or MPS, at a protein concentration of 2 mg/mL and in pres-
nce of 5 mM GSH. Reactions were performed in a final volume of
00 L and in duplicate and started and terminated as described
bove. Correlation analysis of formation rates between MP-SG
nd MSG  was performed using a Spearman’s correlation test
ith GraphPad Prism 5 software (San Diego, CA, USA). P < 0.05
as regarded as statistically significant and all tests were two-
ided.to the web version of this article.)
3. Results
3.1. Validation of the HPLC-UV method for the analysis of MSG
and MSu
A sensitive HPLC-UV-based assay for the quantification of MSG
formed by GSTT2-2 was established. Representative HPLC chro-
matograms of reference compounds and incubation samples are
presented in Fig. 1. The retention times of MSG  and MSu  were 9.6
and 11.1 min, respectively. When incubating MSu  with both recom-
binant human GSTT2-2 (Fig. 1D) and HLC (Fig. 1E), MSG  was found
to be the only metabolite. No MSG  formation was  found in incuba-
tions in the absence of GSTT2-2 fraction (Fig. 1C). The lowest limit
of quantification of MSG  using this HPLC-UV method was  0.13 M,
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Fig. 4. Specificity of GSTT2-2-catalyzed menapthyl GSH-conjugate (MSG) forma-
tion. Incubation conditions, each recombinant human GST isoform at 50 nM was
incubated with 100 M of menapthyl sulfate (MSu) in the presence of 5 mM GSH





































Fig. 5. Enzyme kinetics of human recombinant GSTT2-2 (A) and pooled HLC (B)
probed by MSu  GSH-conjugation reaction. Incubation conditions, (A) recombinant
human GSTT2-2 at 50 nM was  incubated with MSu  ranging from 0.5 to 50 M in
the presence of 5 mM GSH at 37 ◦C for 2 min; (B) pooled HLC at 0.72 mg/mL  was
incubated with MSu ranging from 0.1 to 50 M in the presence of 5 mM GSHSTA2-2, GSTM1-1 at 100 M,  and GSTT2-2 at 50 nM incubating with 100 M MSu
n  the presence of 5 mM GSH for 10 min  at 37 ◦C. Each bar represents average ± range
rom two separate incubations.
s shown in Fig. 1A. Linear calibration curve of MSG  were obtained
rom 0.13 to 32.5 M,  as shown in Fig. 2.
To compare the sensitivity of the HPLC-UV method with that
f the spectrophotometric assay of Gillham [8], incubations were
erformed at different concentrations of pooled HLC. As shown in
ig. 3A, at a HLC-concentration of 0.288 mg/mL  the spectropho-
ometric assay showed only a weak slope with an increase in
bsorbance over 10 min  of approximately 3 times to the noise. Only
t a HLC-concentration of 0.72 mg/mL  the increase in absorbance
as more than 10 times to the noise, which is usually considered
s the lowest limit of quantification. However, when analyzed by
PLC-UV the MSG  could still be quantified accurately in incubation
ontaining 0.0288 mg/mL  pooled HLC, Fig. 3B. Thus the sensitiv-
ty of the current HPLC-UV assay is estimated to be approximately
5-fold higher than that of the spectrophotometric assay.
.2. Isoenzyme selectivity of GST-catalyzed GSH conjugation of
Su
To confirm the selectivity of MSu  as a GSTT2-2-specific sub-
trate, 15 recombinant human GST isoforms were incubated at an
nzyme concentration of 50 nM with 100 M MSu  and in the pres-
nce of 5 mM GSH. As shown in Fig. 4, only GSTT2-2 exhibited a
igh activity in the formation of MSG. None of the other GST iso-
orms showed significant MSG-formation when incubated at 50 nM
nzyme concentration. Because GSTA1-1, GSTA2-2, and GSTM1-1
an have hepatic concentrations up to 100 M, these recombinant
nzymes were also incubated at 100 M with MSu at identical con-
ition as mentioned above. The insert in Fig. 4 shows that these
STs at 100 M only formed small amounts of MSG, being less than
0% of the amount formed by 50 nM GSTT2-2.
.3. Enzyme kinetics of GSH-conjugation of MSu  by recombinant
uman GSTT2-2 and pooled HLC
To further characterize the GSH-conjugation of MSu  by recom-
inant human GSTT2-2 and pooled HLC, enzyme kinetic studies
ere performed. Protein concentrations and incubation times were
rst optimized with regard to linearity of product formation, Sup-
lemental Fig. S2. As shown in Fig. 5A, for recombinant humanat  37 ◦C for 10 min. Solid lines are obtained by nonlinear regression using the
Michaelis–Menten equation or substrate inhibition equation. Inserts show corre-
sponding Eadie-Hofstee plot.
GSTT2-2, the formation of MSG  increased up to an MSu  concentra-
tion of 10 M.  When MSu  concentrations were higher than 10 M,
a decrease in MSG  formation was  observed. By fitting data into sub-
strate inhibition equation, Km was  calculated as 1.7 ± 0.5 M,  Vmax
as 623 ± 84 nmol/min/mg protein, and Ki of 28.1 ± 9.5 M.  Inter-
estingly, no substrate inhibition pattern was observed for pooled
HLC kinetics (Fig. 5B). The Km value in this case was  0.4 ± 0.04 M,
and Vmax value was  132.0 ± 2.7 pmol/min/mg cytosolic protein.
3.4. Characterization of GSTs involved in the GSH-conjugation of
MPS
To characterize the GSTs involved in the GSH-conjugation of
MPS, 105 M MPS  was incubated with 8 M recombinant human
GST isoforms for 5 min  in the presence of 5 mM GSH. As in case of
MSu, under these conditions no spontaneous GSH-conjugation was
detected. As shown in Fig. 6A, GSTT2-2 was the most active isoform.
A few GST isoforms, such as GSTA3-3, A4-4, P1-1*B, P1-1*C and
P1-1*D, weakly catalyzed the GSH-conjugation of MPS, with con-
verting less than 5% MPS  to MP-SG. In contrast, GSTT2-2 exhibited
a remarkably high activity in catalyzing this reaction, with a forma-
tion of 45 M MP-SG. By normalizing GSTT2-2 activity in catalyzing
186 Y. Zhang et al. / Journal of Pharmaceutical and B
Fig. 6. Specificity of GSTT2-catalyzed methyl pyrene glutathione conjugate (MP-SG)
formation. Each GST isoforms at 8 M was incubated with 105 M of methyl pyrene
























f  MP-SG formation; (B) percentage of MP-SG formation with GSTT2-2-catalyzed
ormation of MP-SG normalized as 100%. Data are presented as average ± range of
wo separate incubations.
he formation of MP-SG as 100%, all other GST isoforms showed
ctivities not higher than 13% (Fig. 6B). Table S1 shows the values
f formation of MP-SG by each GST isoform.
.5. Correlation analysis of activities of GSH-conjugation of MSu
nd MPS  in 20 HLC donors
To investigate the correlation between GSH-conjugation of MPS
nd human GSTT2-2 activity, MP-SG and MSG  formation were mea-
ured using a panel of HLC-fractions from 20 donors. As shown in
ig. 7A, a 65-fold variability was observed using MSu  as a substrate
between S1329T and S1399T), reflecting a large variability in hep-
tic GSTT2-2 expression. When using MPS  as a substrate, however,
nly a 3.8-fold difference was found between the most and least
ctive HPLC-fractions, S1449T and S1343T, respectively. Table S2
howed the detailed values of activity of each liver donor in cat-
lyzing formation of MP-SG and MSG. These results implied the
ossibility of large variations of both expression level of GSTT2-2
nd detoxifying profiles of MPS  among population.
Although, a significant correlation was found between GSH-
onjugation of MPS  and MSu, Fig. 7B (Spearman r = 0.86, p < 0.0001)
he line does not cross the origin, suggesting the contribution of
ther cytosolic GSTs, consistent with the results with the recombi-
ant GSTs, Fig. 6.iomedical Analysis 156 (2018) 181–188
4. Discussion
In the current study, an HPLC-UV method was established for the
accurate quantification of human GSTT2-2 in biological samples.
With this method MSG  concentration low to 0.13 M can be accu-
rately quantified. Although several previous studies have used the
spectrophotometric method to determine GSTT2-2 activity [4,6],
the HPLC-UV method was found to be more than 25 times more
sensitive (Fig. 3). The more sensitive HPLC-based method can be
used as a reliable tool for the analysis of in vitro samples containing
low GSTT2-2 activity, of which the sensitivity of spectrophotomet-
ric assay is not high enough. Another advantage of the HPLC-based
method is that it assesses both the formation of MSG and the deple-
tion of MSu  simultaneously, which would not be feasible for the
spectrophotometric method.
Even though the GSH-conjugation of MSu  was considered as
GSTT2-2-specific for decades, the specificity regarding comparison
with other GST isoforms has not been comprehensively investi-
gated. In the current study, by applying the established HPLC-UV
method for quantifying MSG  in MSu  incubations, the high speci-
ficity of MSu  as a substrate for GSTT2-2 is confirmed. Even at
100 M,  the major hepatic GST isoforms GSTA1-1, GSTA2-2, and
GSTM1-1 showed only a few percentage of the activity found with
50 nM GSTT2-2. Because the other GST isoforms are either way less
abundant or absent in the liver, they will not contribute to MSu
GSH-conjugation.
As an application of the HPLC-based method from current
study, enzyme kinetics of MSu  conjugation by purified recombinant
GSTT2-2 and by pooled HLC were characterized. Previously, Hussey
and Hayes [26] reported that purified GSTT2-2 from HLC exhib-
ited a MSu  GSH-conjugation activity of 497 nmol/min/mg protein.
Later on, Tan et al. [27] described that recombinant human GSTT2-
2 expressed in E. coli exhibited a Vmax value of 237 nmol/min/mg
protein and a Km of 4.8 M.  These values are in the same range with
maximal velocity (623 nmol/min/mg protein) and Km (1.7 M)
obtained with the recombinant human GSTT2-2 in the present
study. However, certain discrepancies were found compared with
published data. For example, previous studies have never reported
that enzyme kinetics of GSTT2-2 with MSu  showing a substrate
inhibition pattern (with the same substrate concentration range
used as in the present study), whereas a clear substrate inhibition
curve was observed when MSu  concentrations were higher than
10 M (Fig. 5A). Interestingly, this substrate inhibition pattern was
not observed in pooled HLC, where a typical hyperbolic Michaelis-
Menten curve was  obtained (Fig. 5B). In addition, a 4-fold lower Km
(0.4 M vs. 1.7 M)  was  observed in incubations with pooled HLC.
These differences in enzyme kinetic behaviour between HLC and
recombinant GSTT2-2 may  be explained by interactions of other
cytosolic proteins with GSTT2-2 in case of HLC, which might have
an impact on the binding of MSu  to GSTT2-2. Previous studies have
demonstrated that several GSTs have other functions, next to cat-
alyzing GSH-conjugation or peroxide-hydrolysis, such as physical
interaction with proteins involved in signaling pathways [28]. It
therefore cannot be excluded that GSTT2-2 also has other functions.
Besides enzyme kinetic characterization of GSTT2-2, the novel
HPLC-UV method was  applied to characterize the variability of
GSTT2-2 activity in HLCs. By comparing the activities of a panel
of 20 HLC fractions, a 65-fold variation of GSTT2-2 activity was
observed (Fig. 7), indicating that the inter-individual variability of
this enzyme among population is very large. The basis of the large
variability in this selection of HLC fractions is not known. However
expression of GSTT2-2 can be determined by genetic factors, such as
by mutations in the promotor region [13], and by the absence of the
GSTT2B-pseudogenes. Furthermore, in vitro studies have demon-
strated that transcription of GSTT2 can be strongly upregulated by
plant polyphenols and butyrate [29,30]. The fact that polyphenols
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Fig. 7. Inter-individual variation of GSH-conjugation of MPS  and human GSTT2-2 activity in 20 human liver donors. (A) Formation rates of MP-SG and MSG  of 20 HLC. Activity



















f  MP-SG formation is plotted as left Y-axis and activity of MSG  formation is plotte
pearman correlation analysis between GSH-conjugation of MPS  and human GSTT2
nd butyrate provided protection against oxidative stress caused
y organic peroxides is indicative that GSTT2-2 regulation is one of
he important protective stress responses.
The big variability in GSTT2-2 activity will have most signifi-
ant influence for (geno)toxicants which are highly dependent on
STT2-2 for inactivation. The presence of a sulfate binding pocket
n the crystal structure of GSTT2-2, suggests that the inactivation of
utagenic sulfate esters might be strongly dependent on GSTT2-2.
n the present study, we examined the specificity of human GST
soforms in the detoxification of MPS. MPS  is formed via sulfation
f 1-hydroxylmethylpyrene (HMP), one of the major hydroxyl-
etabolites of the environmental carcinogen methylpyrene [18].
he ultimate carcinogen is considered to be MPS, since this sul-
ate ester can spontaneously degrade to a reactive carbocation,
hich strongly binds to DNA. Our results show that GSTT2-2 is the
ost active GST catalyzing the GSH-conjugation of MPS, with the
ther isoforms showing less than 10% activity compared to that
f GSTT2-2 (Fig. 6). However, the relatively poor correlation withght Y-axis. Each bar represents average ± range from two separate incubations. (B)
ivity (probed by MSu  GSH-conjugation) in 20 human liver donors.
GSTT2-2-activities suggests that other GSTs may also contribute to
GSH-conjugation of MPS  in HLC. Overall, the big variation of both
GSTT2-2 activity and detoxification profiles of MPS  observed in 20
individual HLC underlies a potential mechanism of inter-individual
susceptibility to toxicants which are substrates of GSTT2-2.
In conclusion, in the present study a novel HPLC-based assay
to quantify GSTT2-2 activity from different biological systems was
validated. This new assay allows the quantification of GSTT2-
2 activity in HLC, which was  not feasible with previously-used
method. By applying the assay, specificity of GSTT2-2 in MSu
GSH-conjugation, enzyme kinetics of recombinant human GSTT2-2
and pooled HLC were characterized. More importantly, big inter-
individual variability of GSTT2-2 activity and detoxification profiles
of MPS  were demonstrated in a small set of population, by apply-
ing this assay. Furthermore, the big inter-individual variability of
GSTT2-2 activity might underlie the inter-individual differences of
susceptibility to MPS  carcinogenicity, the ultimate environmental
carcinogen of MP.
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